|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5240848A
(en)
|
1988-11-21 |
1993-08-31 |
Monsanto Company |
Dna sequences encoding human vascular permeability factor having 189 amino acids
|
|
US5328470A
(en)
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5332671A
(en)
|
1989-05-12 |
1994-07-26 |
Genetech, Inc. |
Production of vascular endothelial cell growth factor and DNA encoding same
|
|
US5219739A
(en)
|
1989-07-27 |
1993-06-15 |
Scios Nova Inc. |
DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
|
|
US5194596A
(en)
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
|
EP0500799B1
(en)
|
1989-11-16 |
1998-01-14 |
Duke University |
Particle mediated transformation of animal skin tissue cells
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5672697A
(en)
|
1991-02-08 |
1997-09-30 |
Gilead Sciences, Inc. |
Nucleoside 5'-methylene phosphonates
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
JPH0641183A
(ja)
|
1992-07-23 |
1994-02-15 |
Mitsubishi Kasei Corp |
オリゴヌクレオチド単分子膜
|
|
US5985558A
(en)
*
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
|
US5858988A
(en)
|
1993-02-24 |
1999-01-12 |
Wang; Jui H. |
Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
|
|
US6291438B1
(en)
|
1993-02-24 |
2001-09-18 |
Jui H. Wang |
Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
|
|
EP0691979A1
(en)
|
1993-03-31 |
1996-01-17 |
Sanofi |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
|
TW404844B
(en)
|
1993-04-08 |
2000-09-11 |
Oxford Biosciences Ltd |
Needleless syringe
|
|
DE69514351T2
(de)
|
1994-06-01 |
2000-08-10 |
Hybridon, Inc. |
Verzweigte Oligonukleotide als pathogenhemmende Mittel
|
|
WO1996003500A1
(en)
|
1994-07-26 |
1996-02-08 |
Ltt Institute Co., Ltd. |
Sustance with antiviral activity
|
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
|
AU5545596A
(en)
|
1995-04-28 |
1996-11-18 |
Medtronic, Inc. |
Intraparenchymal infusion catheter system
|
|
US6025335A
(en)
|
1995-09-21 |
2000-02-15 |
Lipitek International, Inc. |
L-Nucleoside Dimer Compounds and therapeutic uses
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US5735814A
(en)
|
1996-04-30 |
1998-04-07 |
Medtronic, Inc. |
Techniques of treating neurodegenerative disorders by brain infusion
|
|
US20080119427A1
(en)
|
1996-06-06 |
2008-05-22 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6177403B1
(en)
|
1996-10-21 |
2001-01-23 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal
|
|
US6042820A
(en)
|
1996-12-20 |
2000-03-28 |
Connaught Laboratories Limited |
Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
|
|
AUPO974597A0
(en)
|
1997-10-10 |
1997-11-06 |
Rhone-Poulenc Agro |
Methods for obtaining plant varieties
|
|
US6472375B1
(en)
|
1998-04-16 |
2002-10-29 |
John Wayne Cancer Institute |
DNA vaccine and methods for its use
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
EP1016726A1
(en)
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gene therapy to promote angiogenesis
|
|
US7608681B2
(en)
|
1999-12-24 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
CN100523215C
(zh)
|
2000-12-01 |
2009-08-05 |
马普科技促进协会 |
介导rna干涉的小rna分子
|
|
EP1386004A4
(en)
|
2001-04-05 |
2005-02-16 |
Ribozyme Pharm Inc |
MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
|
|
EP2428570B1
(en)
|
2001-09-28 |
2018-05-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Microrna molecules
|
|
EP1455815A4
(en)
|
2001-12-19 |
2006-11-02 |
Millennium Pharm Inc |
MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20100240730A1
(en)
|
2002-02-20 |
2010-09-23 |
Merck Sharp And Dohme Corp. |
RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
|
|
US7858367B2
(en)
|
2002-04-30 |
2010-12-28 |
Duke University |
Viral vectors and methods for producing and using the same
|
|
JP5650876B2
(ja)
|
2002-07-19 |
2015-01-07 |
ベス・イスラエル・ディーコニス・メディカル・センター |
子癇前症または子癇の診断方法および治療方法
|
|
US20050106731A1
(en)
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP1578754A4
(en)
|
2002-10-30 |
2006-07-19 |
Makscientific Llc |
ROTARY PHOSPHOLIPIDS SUBSTITUTED ANTIPROTOZOOSES
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
|
US6913890B2
(en)
|
2002-12-18 |
2005-07-05 |
Palo Alto Research Center Incorporated |
Process for preparing albumin protein conjugated oligonucleotide probes
|
|
WO2004061081A2
(en)
|
2002-12-27 |
2004-07-22 |
Ichem Technologies |
Sirna compounds and methods for the downregulation of gene expression
|
|
US20070167384A1
(en)
|
2003-04-02 |
2007-07-19 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
US20040198640A1
(en)
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
|
EP2669377A3
(en)
|
2003-04-17 |
2015-10-14 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
|
CA2528012C
(en)
|
2003-06-02 |
2015-11-24 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
CA2527958C
(en)
|
2003-06-02 |
2014-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of rnai
|
|
DE10326302A1
(de)
|
2003-06-11 |
2004-12-30 |
Gnothis Holding Sa |
Bi-Fluorophor-markierte Sonden zum Nachweis von Nukleinsäuren
|
|
US7790691B2
(en)
|
2003-06-20 |
2010-09-07 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
EP2182063A3
(en)
*
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation of EIF4E expression
|
|
AU2004305111B2
(en)
|
2003-12-19 |
2011-04-28 |
Novartis Vaccines And Diagnostics, Inc. |
Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use
|
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
|
WO2005077333A2
(en)
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
CA2564616C
(en)
|
2004-04-20 |
2016-08-30 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
|
CA2566286A1
(en)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
|
|
JP2008504840A
(ja)
|
2004-06-30 |
2008-02-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
非リン酸骨格結合を含むオリゴヌクレオチド
|
|
US7361468B2
(en)
|
2004-07-02 |
2008-04-22 |
Affymetrix, Inc. |
Methods for genotyping polymorphisms in humans
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
EP2239328A3
(en)
|
2005-08-18 |
2011-01-05 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for treating neurological disease
|
|
WO2007027894A2
(en)
*
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds having enhanced anti-microrna activity
|
|
EP2325315B1
(en)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
|
EP1948674A4
(en)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
|
|
EP1942943A2
(en)
|
2005-11-04 |
2008-07-16 |
Nastech Pharmaceutical Company Inc. |
Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US20070259827A1
(en)
|
2006-01-25 |
2007-11-08 |
University Of Massachusetts |
Compositions and methods for enhancing discriminatory RNA interference
|
|
US9198981B2
(en)
|
2006-02-01 |
2015-12-01 |
The University Of Kentucky |
Modulation of angiogenesis
|
|
US8362229B2
(en)
|
2006-02-08 |
2013-01-29 |
Quark Pharmaceuticals, Inc. |
Tandem siRNAS
|
|
WO2007094218A1
(ja)
|
2006-02-16 |
2007-08-23 |
Gifu University |
修飾オリゴヌクレオチド
|
|
EP1986697B1
(en)
|
2006-02-17 |
2016-06-29 |
GE Healthcare Dharmacon, Inc. |
Compositions and methods for inhibiting gene silencing by rna interference
|
|
US20090306178A1
(en)
|
2006-03-27 |
2009-12-10 |
Balkrishen Bhat |
Conjugated double strand compositions for use in gene modulation
|
|
EP2046993A4
(en)
|
2006-07-07 |
2010-11-17 |
Univ Massachusetts |
RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
EP2081949B1
(en)
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
AU2007310982A1
(en)
|
2006-10-18 |
2008-04-24 |
Marina Biotech, Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
|
US20100279408A1
(en)
|
2006-11-27 |
2010-11-04 |
Enzon Pharmaceuticals, Inc. |
Polymeric short interfering rna conjugates
|
|
WO2008109381A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
|
|
WO2008154482A2
(en)
|
2007-06-08 |
2008-12-18 |
Sirnaomics, Inc. |
Sirna compositions and methods of use in treatment of ocular diseases
|
|
WO2009002944A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
MX2010002113A
(es)
|
2007-08-23 |
2010-03-26 |
Novartis Ag |
Metodos para detectar oligonucleotidos.
|
|
EP3121281B1
(en)
|
2007-08-27 |
2021-03-31 |
1Globe Health Institute LLC |
Compositions of asymmetric interfering rna and uses thereof
|
|
CN101199858A
(zh)
|
2007-10-18 |
2008-06-18 |
广州拓谱基因技术有限公司 |
治疗眼科疾病的多靶点小干扰rna鸡尾酒制剂及制备方法
|
|
TW200927177A
(en)
|
2007-10-24 |
2009-07-01 |
Nat Inst Of Advanced Ind Scien |
Lipid-modified double-stranded RNA having potent RNA interference effect
|
|
EP2229186A2
(en)
|
2007-12-04 |
2010-09-22 |
Alnylam Pharmaceuticals Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
US20110081362A1
(en)
|
2008-01-31 |
2011-04-07 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
CA2731779A1
(en)
|
2008-07-24 |
2010-01-28 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
AU2009273878A1
(en)
*
|
2008-07-25 |
2010-01-28 |
Alnylam Pharmaceuticals, Inc. |
Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
CA2739672C
(en)
|
2008-10-15 |
2017-03-28 |
F. Hoffmann-La Roche Ag |
Oligonucleotide detection method using a peptide nucleic acid probe
|
|
ES2563984T3
(es)
|
2008-10-22 |
2016-03-17 |
Quark Pharmaceuticals, Inc. |
Métodos para el tratamiento de trastornos oculares
|
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
EP2405921A4
(en)
|
2009-01-26 |
2013-05-22 |
Protiva Biotherapeutics Inc |
COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
KR101141544B1
(ko)
|
2009-03-13 |
2012-05-03 |
한국과학기술원 |
에스아이알엔에이 다중 접합체 및 이의 제조방법
|
|
US8426581B2
(en)
|
2009-03-27 |
2013-04-23 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of the FCεR1α gene
|
|
US8309356B2
(en)
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
|
US8987222B2
(en)
|
2009-04-08 |
2015-03-24 |
University Of Massachusetts |
Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
GB0910723D0
(en)
|
2009-06-22 |
2009-08-05 |
Sylentis Sau |
Novel drugs for inhibition of gene expression
|
|
HUE026020T2
(en)
|
2009-08-27 |
2016-05-30 |
Idera Pharmaceuticals Inc |
Preparation for inhibiting gene expression and its uses
|
|
EP3626823A1
(en)
|
2009-09-11 |
2020-03-25 |
Ionis Pharmaceuticals, Inc. |
Modulation of huntingtin expression
|
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
|
EP2513337A4
(en)
*
|
2009-12-17 |
2013-12-25 |
Merck Sharp & Dohme |
METHOD FOR QUICKLY EVALUATING THE PERFORMANCE OF SHORT INTERFERING RNA WITH NEW CHEMICAL MODIFICATIONS
|
|
ES2733708T3
(es)
|
2010-02-08 |
2019-12-02 |
Ionis Pharmaceuticals Inc |
Reducción selectiva de variantes alélicas
|
|
WO2011109698A1
(en)
|
2010-03-04 |
2011-09-09 |
Rxi Pharmaceuticals Corporation |
Formulations and methods for targeted delivery to phagocyte cells
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
|
WO2011125943A1
(ja)
|
2010-04-01 |
2011-10-13 |
日本新薬株式会社 |
修飾オリゴヌクレオチド
|
|
WO2011139702A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
|
WO2012005898A2
(en)
|
2010-06-15 |
2012-01-12 |
Alnylam Pharmaceuticals, Inc. |
Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
|
|
US8946185B2
(en)
|
2010-06-18 |
2015-02-03 |
Lsip, Llc |
Agent for suppressing expression of dominant allele
|
|
WO2012003330A2
(en)
|
2010-06-30 |
2012-01-05 |
Stratos Genomics, Inc |
Multiplexed identification of nucleic acid sequences
|
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US10378016B2
(en)
|
2010-12-06 |
2019-08-13 |
Children's Medical Center Corporation |
Composition and method for oligonucleotide delivery
|
|
AU2011343647A1
(en)
|
2010-12-16 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
|
RU2013132681A
(ru)
|
2010-12-16 |
2015-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы репликации вирусов гриппа
|
|
JP2013545817A
(ja)
|
2010-12-16 |
2013-12-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
インフルエンザウイルス複製阻害物質
|
|
RU2013117288A
(ru)
|
2010-12-17 |
2015-01-27 |
Эрроухэд Рисерч Корпорейшн |
СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
|
|
AU2012223366B2
(en)
|
2011-03-03 |
2017-02-23 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
|
GB201105137D0
(en)
|
2011-03-28 |
2011-05-11 |
Isis Innovation |
Therapeutic molecules for use in the suppression of Parkinson's disease
|
|
WO2012143796A2
(en)
|
2011-04-21 |
2012-10-26 |
Institut Pasteur Korea |
Anti-inflammation compounds
|
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
CN108148838B
(zh)
|
2012-05-22 |
2026-07-31 |
奥利克斯医药有限公司 |
具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
|
|
BR112015000236A2
(pt)
|
2012-07-10 |
2017-06-27 |
Baseclick Gmbh |
moléculas de ácidos nucleicos modificadas por anandamida
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
CA2889044A1
(en)
|
2012-11-15 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
BR112015013105B1
(pt)
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
|
US20140200124A1
(en)
|
2013-01-15 |
2014-07-17 |
Karen Michelle JAMES |
Physical Therapy Device and Methods for Use Thereof
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
EP3007705A4
(en)
|
2013-06-12 |
2017-02-15 |
Oncoimmunin, Inc. |
Systemic in vivo delivery of oligonucleotides
|
|
CN105324119A
(zh)
|
2013-06-16 |
2016-02-10 |
国立大学法人东京医科齿科大学 |
具有外显子跳跃效应的双链反义核酸
|
|
US9862350B2
(en)
|
2013-08-12 |
2018-01-09 |
Tk Holdings Inc. |
Dual chambered passenger airbag
|
|
GB201315141D0
(en)
|
2013-08-23 |
2013-10-09 |
Logicor R & D Ltd |
Improvements to electric heating systems and method of use thereof
|
|
WO2015057847A1
(en)
|
2013-10-16 |
2015-04-23 |
Cerulean Pharma Inc. |
Conjugates, particles, compositions, and related methods
|
|
US10752940B2
(en)
|
2013-11-08 |
2020-08-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
|
CA2938084A1
(en)
|
2014-01-27 |
2015-07-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Oligonucleotides and methods for treatment of cardiomyopathy using rna interference
|
|
US10513710B2
(en)
|
2014-04-18 |
2019-12-24 |
University Of Massachusetts |
Exosomal loading using hydrophobically modified oligonucleotides
|
|
EP3137606A4
(en)
|
2014-05-01 |
2018-04-25 |
Larry J. Smith |
METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
|
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
|
IL316808A
(en)
*
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
AU2015329974B2
(en)
|
2014-10-10 |
2019-06-20 |
F. Hoffmann-La Roche Ag |
GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
|
|
TWI769565B
(zh)
|
2014-11-10 |
2022-07-01 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
WO2016083623A1
(en)
|
2014-11-28 |
2016-06-02 |
Silence Therapeutics Gmbh |
Means for the treatment of pre-eclampsia
|
|
AU2015370903B2
(en)
|
2014-12-24 |
2021-06-17 |
Uniqure Ip B.V. |
RNAi induced huntingtin gene suppression
|
|
CA3255657A1
(en)
|
2015-02-10 |
2025-12-01 |
Genzyme Corporation |
VARIANT RNAi
|
|
MX2017011422A
(es)
*
|
2015-03-17 |
2017-11-10 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen del factor xii.
|
|
RS60762B1
(sr)
|
2015-04-03 |
2020-10-30 |
Univ Massachusetts |
Oligonukleotidna jedinjenja za ciljane irnk hantingtina
|
|
EP3929293A3
(en)
|
2015-04-03 |
2022-03-16 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
WO2016161378A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
WO2016164866A1
(en)
|
2015-04-10 |
2016-10-13 |
Hudsonalpha Institute For Biotechnology |
METHOD FOR BLOCKING miRNA
|
|
IL316159A
(en)
|
2015-06-15 |
2024-12-01 |
Mpeg La Llc |
Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
|
|
US20170009304A1
(en)
|
2015-07-07 |
2017-01-12 |
Splicingcodes.Com |
Method and kit for detecting fusion transcripts
|
|
CN117965536A
(zh)
|
2015-07-22 |
2024-05-03 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
EP3331573A4
(en)
|
2015-08-06 |
2019-02-27 |
City of Hope |
THERAPEUTIC CELL-INTERNALIZING CONJUGATES
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
MA46427A
(fr)
*
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
CN105194689A
(zh)
|
2015-10-10 |
2015-12-30 |
湖南中楚博生物科技有限公司 |
一种基于siRNA的双偶联复合物
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
WO2017174572A1
(en)
|
2016-04-04 |
2017-10-12 |
F. Hoffmann-La Roche Ag |
Nucleic acid sample preparation methods
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
WO2018031933A2
(en)
*
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
WO2018041973A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
US11015198B2
(en)
*
|
2017-04-05 |
2021-05-25 |
Silence Therapeutics Gmbh |
Products and compositions
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018237245A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Massachusetts |
TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
|
|
WO2019035038A1
(en)
|
2017-08-18 |
2019-02-21 |
The Procter & Gamble Company |
Cleaning agent
|
|
CN111163938B
(zh)
|
2017-10-12 |
2022-09-09 |
艾利丹尼森公司 |
低放气清洁胶黏剂
|
|
HRP20231063T1
(hr)
|
2017-10-13 |
2023-12-22 |
Novo Nordisk Health Care Ag |
Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
|
|
EP3709990A4
(en)
|
2017-11-17 |
2021-12-01 |
The Regents of the University of California |
MANIPULATION OF THE RETIC ACID SIGNAL PATH
|
|
EP3550021A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions for inhibiting expression of a target gene
|
|
CA3098623A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
JP7583712B2
(ja)
|
2018-05-30 |
2024-11-14 |
ノバルティス アーゲー |
脂質修飾された核酸化合物および方法
|
|
BR112021002440A2
(pt)
|
2018-08-10 |
2021-05-04 |
University Of Massachusetts |
oligonucleotídeos modificados visando snps
|
|
WO2020041769A1
(en)
|
2018-08-23 |
2020-02-27 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
CN113614232A
(zh)
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
CA3133241A1
(en)
|
2019-03-15 |
2020-09-24 |
University Of Massachusetts |
Oligonucleotides for tissue specific apoe modulation
|
|
EP3946369A4
(en)
|
2019-03-26 |
2023-10-18 |
University Of Massachusetts |
MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
|
|
AU2020252020A1
(en)
|
2019-03-29 |
2021-11-11 |
University Of Massachusetts |
Oligonucleotide-based modulation of C90RF72
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
US20210115442A1
(en)
*
|
2019-08-23 |
2021-04-22 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
EP4090744A4
(en)
|
2020-01-17 |
2024-04-10 |
Anastasia Khvorova |
UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS
|
|
EP4110913A4
(en)
|
2020-02-28 |
2024-07-24 |
University of Massachusetts |
OLIGONUCLEOTIDES FOR PRNP MODULATION
|
|
JP2023518439A
(ja)
|
2020-03-18 |
2023-05-01 |
ユニバーシティー オブ マサチューセッツ |
Ｍａｐｔ調節のためのオリゴヌクレオチド
|
|
CN115605226A
(zh)
|
2020-03-26 |
2023-01-13 |
纽特莱特公司（Us） |
具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体
|
|
AU2021244600A1
(en)
|
2020-03-26 |
2022-11-03 |
University Of Massachusetts |
Synthesis of modified oligonucleotides with increased stability
|
|
US12344839B2
(en)
|
2020-03-27 |
2025-07-01 |
University Of Massachusetts |
Dual-acting siRNA based modulation of C9orf72
|
|
WO2021216556A2
(en)
|
2020-04-20 |
2021-10-28 |
University Of Massachusetts |
Oligonucleotides for msh3 modulation
|
|
CA3174079A1
(en)
|
2020-05-26 |
2021-12-02 |
Anastasia Khvorova |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
EP4158028A4
(en)
|
2020-05-28 |
2024-10-02 |
University Of Massachusetts |
OLIGONUCLEOTIDES FOR THE MODULATION OF SARS-COV-2
|
|
EP4181932A4
(en)
|
2020-07-16 |
2025-07-16 |
Univ Massachusetts |
CONJUGATED OLIGONUCLEOTIDES FOR SPECIFIC TISSUE DELIVERY
|
|
WO2022031591A2
(en)
|
2020-08-03 |
2022-02-10 |
University Of Massachusetts |
Oligonucleotides for htt-1a modulation
|
|
WO2022109398A1
(en)
|
2020-11-23 |
2022-05-27 |
University Of Massachusetts |
Oligonucleotides for dgat2 modulation
|
|
IL309334A
(en)
|
2021-06-23 |
2024-02-01 |
Univ Massachusetts |
Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
|
|
WO2023014654A2
(en)
|
2021-08-02 |
2023-02-09 |
University Of Massachusetts |
Oligonucleotides for htt-1a modulation
|
|
WO2023081908A2
(en)
|
2021-11-08 |
2023-05-11 |
University Of Massachusetts |
Oligonucleotides for sod1 modulation
|
|
US20230340475A1
(en)
|
2021-12-17 |
2023-10-26 |
University Of Massachusetts |
Oligonucleotides for mlh1 modulation
|
|
WO2023114989A2
(en)
|
2021-12-17 |
2023-06-22 |
University Of Massachusetts |
Oligonucleotides for mlh3 modulation
|
|
WO2023133550A2
(en)
|
2022-01-10 |
2023-07-13 |
University Of Massachusetts |
Oligonucleotides for mecp2 modulation
|
|
US20230392146A1
(en)
|
2022-03-11 |
2023-12-07 |
University Of Massachusetts |
Oligonucleotides for app modulation
|
|
US20230416735A1
(en)
|
2022-04-14 |
2023-12-28 |
University Of Massachusetts |
Oligonucleotides for atn1 modulation
|
|
JP2025532984A
(ja)
|
2022-09-30 |
2025-10-03 |
ユニバーシティー オブ マサチューセッツ |
オリゴヌクレオチドの眼送達
|